Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Fontanesi
  NCT04348409		 RCTnitazoxanideplaceboCOVID-19 mild to moderateNA
25/25 no results
    Holubar M
          NCT04346628    		 RCTfavipiravir placeboCOVID-19 mild to moderateNA
    		75/74 inconclusive
    • inconclusive 24 % decrease in viral clearance ,viral clearance (time to event analysis only) (PE)
    Kirti
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    RIVET-COV (Mohan) (12mg and 24mg)
          CTRI/2020/06/026001    		 RCTivermectinplaceboCOVID-19 mild to moderatehigh
    		104/52 inconclusive
    • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
    Shenoy S
          NCT04529499    		 RCTfavipiravir placeboCOVID-19 mild to moderatehigh
    		175/178 inconclusive
    • inconclusive 1 % decrease in clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
    Shinkai
          JapicCTI-205238    		 RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
    		107/49 safety concern
    • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    Silva
          NCT04463264    		 RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
    		33/13 inconclusive
      Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
      		48/24 suggested
      • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
      Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
      Chaccour
              NCT04390022      		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
      		12/12 inconclusive
      • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
      Rocco
              NCT04552483      		 RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
      		238/237 inconclusive
      • inconclusive 19 % decrease in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
      2 studies excluded by filtering options (0 RCT / 2 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons